Introduction: Murine microglia expressing the Alzheimer's disease-linked TREM2 R47H mutation display variable decrease in phagocytosis, while impaired phagocytosis is reported following loss of TREM2. However, no data exist on TREM2 1/R47H human microglia. Therefore, we created human pluripotent stem cell (hPSC) monocytes and transdifferentiated microglia-like cells (tMGs) to examine the effect of the TREM2 1/R47H mutation and loss of TREM2 on phagocytosis. Methods: We generated isogenic TREM2 1/R47H , TREM2 1/2 , and TREM2 2/2 hPSCs using CRISPR/ Cas9. Following differentiation to monocytes and tMGs, we studied the uptake of Escherichia coli fragments and analyzed amyloid plaque clearance from cryosections of APP/PS1 1/2 mouse brains. Results: We demonstrated that tMGs resemble cultured human microglia. TREM2 1/2 and TREM2 2/2 hPSC monocytes and tMGs phagocytosed significantly less E. coli fragments and cleared less amyloid plaques than wild-type hPSC progeny, with no difference for TREM2
Introduction
Abnormal amyloid processing and plaque formation in patients with familial Alzheimer's disease (AD) are caused by mutations in the APP or PSEN1/2 gene that directly affect the production of amyloid [1] [2] [3] . However, late-onset AD (LOAD) and Nasu-Hakola disease (NHD) patients, who lack these mutations, also present with amyloid pathology and dementia [4] [5] [6] . Genome-wide association studies revealed that mutations in immune genes, including TREM2, are risk factors for patients with LOAD [3] [4] [5] 7, 8] , while homozygous loss of cell surface-expressed TREM2 on microglia causes NHD [9, 10] . Thus, microglia dysfunction not only occurs in response to neurodegeneration but may also be sufficient to induce amyloid pathology and contributes to disease progression [11] [12] [13] .
TREM2 is expressed intracellular and on the membrane of myeloid cells, in particular microglia [14] [15] [16] [17] . Singlenucleotide polymorphisms (SNPs) in TREM2 significantly increase the risk of developing multiple neurological disorders. In individuals with a heterozygous TREM2 R47H mutation (TREM2
1/R47H
), there is a 3-fold increased risk for LOAD, approximating the risk imposed by apolipoprotein E4 (APOE ε4) [4, 5, 18, 19] . Although TREM2 appears to be crucial for microglial activation [20] , and is required for a broad range of microglial responses to neurodegeneration (e.g., proliferation, migration, phagocytosis, inflammatory response, survival, clustering, cellular energetic and biosynthetic metabolism) [21] [22] [23] [24] [25] [26] [27] [28] , it remains unclear how TREM2 mutations cause AD pathology. One possibility would be that certain TREM2 mutations directly affect amyloid clearance. The R47H mutation was shown to not impair amyloid plaque load in mice [27] but to reduce amyloid compaction, which was also observed upon TREM2 deficiency [23] . Nevertheless, murine in vivo studies revealed variable results on plaque load following loss of TREM2, which appeared to be time dependent [22] . In vitro, decreased phagocytosis of several ligands (e.g., latex beads, pHrodo-linked Escherichia coli fragments, amyloid b fragments [29] , neurons [30, 31] , and reduced amyloid plaque clearance [32] ) has consistently been demonstrated in TREM2-deficient mouse macrophages, microglia, and HEK cell lines. However, Brownjohn et al. recently observed no defect in E. coli uptake in microglia-like cells derived from human pluripotent stem cells (hPSCs) carrying mutations that cause a decrease/absence of mature TREM2 membrane expression [33] . The effect of the R47H mutation on in vitro phagocytosis has solely been studied in transduced HEK cells and mouse microglia with inconsistent results: R47H transduced HEK cells displayed a reduced uptake of latex beads, and amyloid b 1-42 , but not pHrodolinked E. coli fragments [29] . In addition, the degree of reduced latex bead uptake differed between R47H mutant transduced HEK cells [29] and microglia [34] , and amyloid plaque removal has so far not been assessed.
To examine if the AD-associated heterozygous R47H mutation, or heterozygous or homozygous loss of TREM2, can directly impair phagocytosis by human microglia, we generated hPSC-derived TREM2 1/R47H , TREM2 1/2 , and TREM2 2/2 monocytes and microglia-like cells and performed two independent phagocytosis assays including an ex vivo human amyloid plaque clearance assay.
Methods

Human PSC differentiation to monocytes and transdifferentiated microglia-like cells
Monocytes were differentiated according to the protocol published by Yanagimachi et al. [35] . On days 17, 21, 25, 28, and 32, nonadherent cells were harvested and monocytes selected using CD14-labeled magnetic beads (Miltenyi), according to the company's specifications. Monocytes were used for further analysis on the day of collection. To transdifferentiate monocytes to microglia-like cells (transdifferentiated microglia-like cells [tMGs] ), a minimum of 500,000 freshly harvested monocytes were plated per well of a 6-well plate (Corning) in the microglia differentiation medium (Neurobasal medium, N2, B27, lactic acid, sodium pyruvate, glutamax, biotin, ascorbic acid, NaCl, Albumax I, and Pen/ Strep.) supplemented with 10 ng/mL of IL34 and M-CSF, resembling the microglia medium described by Muffat et al. [36] . The medium was changed every day. The yield of monocytes per 6-well plate (5-10 colonies/well) varied between 5 ! 10 5 and 1 ! 10 6 , and an equal number of adherent tMGs were obtained. hPSCs, a CRISPR/Cas9, gRNA B, and the same donor plasmid were used. To create TREM2 1/R47H hPSCs, 2 ! 10 6 single cells of the heterozygously targeted clone were nucleofected with 4 mg of piggyBac (PB) transposase plasmid and negative selection with fialuridine, also known as 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) (1:8000-1:2500; 0.5 mM in water), was applied to select for cells wherein the selection cassette was removed. Of note, the H9 WT line from which the TREM2 1/R47H , TREM2 1/2 , and TREM2 2/2 lines were created carries an APOE ε3/ε4 genotype [37] .
Genome engineering
Ex vivo amyloid plaque clearance
The ex vivo amyloid plaque clearance assay was performed as described by Xiang et al., 2016 [32,38] ; 10-mmthick cryosections from 6-month-old APP/PS1 1/2 mouse brains [39] were collected onto poly-L-lysine-coated glass coverslips, dried at room temperature for 1 h, followed by incubation with 5 mg/mL mAb11 antibody in phosphate-buffered saline (PBS) for 1 h at 37 C. Human PSC monocytes were seeded at 3 ! 10 5 and tMGs at 2 ! 10 5 per well in 12-well plates and incubated at 37 C with 5% CO 2 for 16 h/24 h in either a monocyte medium (day 13 composition) or microglia differentiation medium with IL34 and M-CSF for tMGs. TREM2 WT (wild-type), TREM2
1/R47H , TREM2 1/2 , or TREM2 2/2 cells were plated on consecutively cut cryosections to ensure comparable amyloid plaque load. We also included APP/PS1 1/2 cryosections without hPSC progeny as a control. After incubation, coverslips were fixed with 4% paraformaldehyde for 15 minutes, permeabilized using 0.1% Triton in 1! PBS; blocked for 1 h 
Additional methods
Other methods used in this study can be found in the Supplementary Methods online.
Statistical methods
Data represent minimum of two to three independent differentiations with technical replicates, means with SEM, and P values by unpaired t-test: *P .05; **P , .005; ***P , .001; and ****P , .0001.
Results
Differentiation to monocytes and tMGs
Monocytes were generated using the Yanagimachi protocol [35] (Fig. 1A and Supplementary Fig. 1A ). From day 17 onward, CD14
1 monocytes were isolated from the medium by magnetic-activated cell sorting (MACS). MACS-isolated monocytes were nearly 100% CX3CR1 and CD14 positive (Fig. 1B) . Once transdifferentiated to tMGs, cells became adherent and stained nearly 100% TMEM119 and IBA1 positive ( Supplementary Fig. 1B ).
Transdifferentiated microglia-like cells expressed significantly higher levels of microglial gene transcripts (P2RY12, PROS1, TGFBR1, OLFML3, C1Q, CSF1R, TMEM119, APOE, and TREM2 [ Fig. 1C ]) compared with human peripheral blood (PB) monocytes, measured by qRT-PCR. Transcripts for HEXB were already highly expressed in PB monocytes, and CX3CR1 transcripts were lower in tMGs than PB monocytes (Fig. 1C) . Compared with hPSC monocytes, typical microglial transcripts were not higher expressed in tMGs, except for TREM2, APOE, and CSF1R (Fig. 1C) , whereas transcript levels of CD45, a marker of definitive bone marrow-derived macrophages [41] , were lower in both hPSC monocytes and tMGs than PB monocytes (Fig. 1C) . However, tMGs expressed significantly lower levels of the monocyte gene CCR2 and the monocyte-specific transcription factor KLF4 [41] ( Fig. 1C ) than hPSC monocytes and PB monocytes. Thus, this limited transcriptional analysis suggested that hPSC-derived tMGs resemble microglia. Surprisingly, monocytes derived via the Yanagimachi protocol from hPSCs [35] were more similar to tMGs than PB monocytes (Fig. 1C ). This was confirmed by genome-wide RNA sequencing (RNAseq) studies, where we compared tMGs and hPSC monocytes generated in this study with the RNAseq data from Abud et al. [41] . Principal component analysis of both data sets demonstrated that tMGs and hPSC monocytes generated from our study clustered together with in vitro cultured human fetal and adult human microglia, and with hPSC-induced microglia-like cells, but not with CD14
1 PB monocytes (Fig. 1D ). This was further confirmed by the similarity in the gene expression patterns observed for the normalized log1p CPM (counts per million) for a set of genes of the two RNAseq studies ( Supplementary Fig. 1C ). Thus, hPSC monocytes derived using the Yanagimachi protocol differ from PB monocytes, which we hypothesize is caused by in vitro culture. Indeed, in vitro culture of PB monocytes for 48 h in the culture medium used to create monocytes from hPSCs increased expression of a set of microglial genes ( Supplementary  Fig. 1D ).
Thus, we do not only provide evidence that the tMGs described in the present study resemble microglia-like cells generated in other published studies, and cultured human 
Genome engineering of TREM2 mutant hPSC lines
To assess the role of TREM2 mutations or loss of TREM2 in human microglia, we used CRISPR/Cas9-mediated genome engineering. We inserted by homologous recombination a donor construct, encompassing the R47H SNP, a 6-kB hygromycin/thymidine kinase selection cassette between two piggyBac inverted repeat sequences, and a silent mutation (CTCA.TTAA), in exon 2 of TREM2 (Fig. 2A) . Inducing a silent TTAA mutation within 300 bp of the wanted R47H SNP was needed to enable piggyBac excision of the selection cassette after targeting [42] (Fig. 2A) . Insertion of the 6-kB cassette in exon 2, in either one allele (CRISPR/Cas9 nickases 1 gRNA A and B) [43] or both alleles (CRISPR/Cas9 1 gRNA B), interferes with its transcription and resulted in a TREM2
1/2 and TREM2
2/2
hPSC line (Supplementary Table 1 ). Following excision of the selection cassette by piggyBac transposase [42] , the R47H heterozygous line (TREM2 1/R47H ) was created from the TREM2 1/2 line ( Fig. 2A) . Successful targeting and subsequent removal of the selection cassette from the TREM2 1/ 2 line to create the TREM2 1/R47H mutant line was confirmed by presence and absence of green fluorescent protein expression (emission in the FITC field) before and after piggyBac excision (Fig. 2B) . Quality control studies consisted of sequencing of TREM2 exon 2 (G.A, R47H) ( Fig. 2C Fig. 2A, B; Supplementary Table 2) , sequencing of the top 3 predicted off-target sites of each gRNA ( Supplementary Fig. 2C, D) , array comparative genome hybridization ( Supplementary Fig. 2E ), SNP profiling for cell identity, and pluripotency assays (immunohistochemistry and score cards) (Supplementary Fig. 2F ).
Characterization of hPSC monocytes and tMGs derived from TREM2 WT, TREM2
1/R47H , TREM2 1/2 , and TREM2 2/2 hPSCs
Quantitative RT-PCR analysis demonstrated that heterozygous or homozygous cassette integration in exon 2 of TREM2 resulted in a reduction of TREM2 mRNA in TREM2 1/2 compared with WT progeny (reduction of 1/2 3 DCt), with a greater reduction in TREM2 2/2 compared with TREM2 1/2 progeny (reduction of 1/2 5 DCt) (Fig. 3A) .
Following differentiation of the different TREM2 lines to hPSC monocytes and tMGs, we observed a similar increased expression of monocyte-related genes in all TREM2 hPSC monocytes (CD14, CD45, CCR2, DAP12, and CX3CR1;
Supplementary Table 3) and reduced OCT4 expression relative to WT hPSCs (Fig. 3B) . Moreover, expression of a panel of microglia markers (Supplementary Table 3 ) was highly similar in the different TREM2 tMG variants relative to WT tMGs (Fig. 3C) .
We next compared the transcriptome of WT and TREM2 2/2 tMGs by RNA sequencing. Supplementary Table 4 shows the top affected functions that were upregulated or downregulated in TREM2 2/2 tMGs compared with WT tMGs. The highest downregulated functions included extracellular matrix structure and transmembrane transporter activity. The highest upregulated functions in TREM2 2/2 tMGs included receptor-ligand activity, receptor-regulator activity, calcium ion binding, and cytokine activity (Supplementary Table 4 and 5).
TREM2
1/2 and TREM2 2/2 , but not TREM2
1/R47H
monocytes and tMGs, phagocytosed significantly less pHrodo-linked E. coli fragments
We assessed the ability of WT, TREM2 1/R47H , TREM2
1/2 and TREM2 2/2 monocytes and tMGs to phagocytose pHrodo-linked E. coli fragments using 100,000 cells and analyzed after 10 minutes of incubation. Compared with WT cells, TREM2 1/2 and TREM2 2/2 monocytes and tMGs phagocytosed significantly less E. coli fragments (Fig. 4A,  B; Supplementary Fig. 3 ). In contrast, the TREM2 1/R47H mutation in tMGs did not affect phagocytosis of E. coli (Fig. 4B) and decreased phagocytosis by hPSC monocytes by only 4% compared with WT cells (Fig. 4A,  Supplementary Fig. 3 ).
Amyloid plaque clearance from APP/PS1
1/2 cryosections was reduced for TREM2 1/2 and TREM2 2/2 , but not TREM2 1/R47H monocytes and tMGs
We also plated WT, TREM2
1/R47H
, TREM2 1/2 , and TREM2 2/2 monocytes and tMGs onto cryosections from 6-month-old APP/PS1 1/2 mouse brains, containing amyloid plaques [39] . Xiang et al. [32] demonstrated that preincubation of APP/PS1 1/2 cryosections with mAb11 antibody, a murine IgG2a antibody with similar amyloid binding properties as the clinically used anti-Ab antibody Gantenerumab [44, 45] , triggers amyloid plaque clearance by exogenously added mouse microglia. Similarly, hPSC monocytes robustly removed amyloid plaques after 48 h (Supplementary Fig. 4A ), as shown by reduced staining of Ab plaques using thiazine red and anti-amyloid b antibody (3552 Ab-green), which was not observed in the absence of mAb11 (Supplementary Fig. 4A ).
We next determined the kinetics of amyloid removal by staining brain cryosections with thiazine red (amyloid pla- (51) is highlighted in a darker color. All data represent N 5 3, means with SEM, and P values by unpaired t-test; *P .05; **P , .005; ***P , .001; ****P , .0001. Abbreviations: hPSC, human pluripotent stem cell; WT, wild-type. 4B ). However, when tMGs were plated on the cryosections for 24 h, most plaques were cleared ( Supplementary Fig.  4C ). Therefore, we assessed plaque clearance by tMGs 16 h after plating ( Supplementary Fig. 4C ) and clearance by hPSC monocytes 24 h after plating on cryosections (Fig. 5A ).
We observed a significant decrease in plaque removal by TREM2 1/2 monocytes and tMGs compared with WT cells at 24 h and 16 h, respectively (Fig. 5A, B, C) . Similar results were obtained for TREM2 2/2 tMGs (Fig. 5C ). Although the difference between the number of plaques for WT and TREM2 2/2 monocytes was not significantly different due to interexperimental variability (Fig. 5B) , the persistent plaque area was significantly increased for TREM2 2/2 compared with WT monocytes (Fig. 5B) . Confocal images illustrated amyloid plaque (thiazine red) removal by WT, TREM2
1/2 , and TREM2 2/2 progeny (LAMP1 1 , green, to identify lysosomes in monocytes and tMGs [46] ) compared with slices without human cells (Fig. 5D) . By contrast, TREM2
1/R47H mutant monocytes and tMGs did not affect the number of plaques nor the total plaque size (Fig. 5B, C) .
Discussion
As loss of TREM2 surface expression and the clinical TREM2 1/R47H heterozygous mutation result in amyloid pathology [4] [5] [6] , we here assessed if such mutant microglia might show reduced amyloid plaque clearance. We demonstrated, using a series of isogenic genome-edited hPSCs differentiated to monocytes and tMGs, that phagocytosis of both E. coli fragments and human amyloid plaques is significantly impaired for TREM2 1/2 and TREM2 2/2 , but not TREM2 1/R47H hPSC progeny. First, we differentiated hPSCs to monocytes using the Yanagimachi protocol [35] . Magnetically isolated CD14 1 monocytes were then further transdifferentiated to tMGs using a combination of recombinant human M-CSF and IL34, as in Douvaras et al. (2017) [47] . Compared with PB monocytes, a set of microglial genes was significantly higher expressed in tMGs, with the exception of CX3CR1. This is in line with Douvaras et al. (2017) who suggested that expression of CX3CR1 by microglia is seen chiefly early during microglial development. When we compared the normalized log1p CPM for CX3CR1 of tMGs from our RNAseq study pooled with cultured fetal and adult human microglia, PB monocytes, and hPSCinduced microglia-like cells (RNAseq from Abud et al., 2017 [41] ), CX3CR1 was more highly expressed in PB monocytes compared with microglia (-like) samples.
Thus, under which circumstances CX3CR1 is expressed should be further studied.
Comparison of tMGs with hPSC monocytes and PB monocytes somewhat surprisingly demonstrated that hPSC monocytes were quite similar to tMGs, whereas both differed significantly from PB monocytes. This was shown by qRT-PCR analysis for a set of microglial genes and confirmed based on the RNAseq studies from us and Abud et al. [41] . Thus, hPSC-tMGs resemble hPSCmicroglia described in other studies, as well as cultured human microglia. However, so-called monocytes differentiated from hPSCs using the Yanagimachi protocol also resemble cultured microglia and much less PB monocytes. As culture of PB monocytes for 48 h in the hPSCmonocyte culture medium induced the expression of microglial genes, we hypothesize that this is due to the in vitro culture.
The best model to study the role of TREM2 mutations would be human brain-derived microglia, which is difficult due to limited access to human brains. However, the ability to create microglia-like cells from hPSCs can now overcome this limitation. Therefore, we created a series of isogenic hPSCs by either knocking in the TREM2 1/R47H mutation in one allele or knocking out one or both copies of TREM2 (TREM2 1/2 and TREM2 2/2 hPSCs). These lines allow for the analysis of the effect of heterozygous or homozygous loss of TREM2 as well as the role of the heterozygous R47H mutation on microglial function, and this is independent of possible genetic modifiers. Quantitative RT-PCR for TREM2 transcripts demonstrated that TREM2 transcripts were significantly decreased in TREM2 1/2 and even more in TREM2 2/2 hPSC monocytes and tMGs. Moreover, TREM2 genome engineered lines were successfully differentiated to tMGs, based on the expression profile of a panel of microglial genes.
In agreement with current literature [29] , we demonstrated decreased phagocytosis of pHrodo-linked E. coli fragments by TREM2 1/2 and TREM2 2/2 tMGs. We also found reduced amyloid plaque clearance by TREM2 = more profound than that of TREM2 1/2 tMGs, we hypothesize that phagocytosis is directly affected once TREM2 mRNA expression is decreased at least 80% compared with WT tMGs.
Our data on the TREM2 1/R47H tMGs are mostly in line with data from Kleinberger et al. [29] who used R47H transduced HEK cells, also demonstrating no decrease in pHrodo-linked E. coli uptake. However, although we did not observe reduced amyloid plaque clearance by TREM2 1/R47H tMGs, the Kleinberger study found decreased uptake of amyloid b 1-42 by R47H transduced HEK cells.
This may reflect differences between amyloid plaques and amyloid b , or the cell type studied.
To assess amyloid plaque clearance from cryosections, it was necessary to guide the hPSC monocytes and tMGs to the plaques with mAb11 because in the absence thereof, amyloid phagocytosis was barely detectable [32] , and cryosections disintegrated after 3-4 days of co-culture. It is likely that without use of mAb11, microglia-like cells try to remove the necrotic nonviable tissue of the repeatedly frozen and thawed cryosected mouse brain, which interfered with the specific phagocytosis of amyloid plaques. The use of the mAb11 precluded assessment of a possible defect in migration caused by loss of TREM2/TREM2
1/R47H cells. In addition, we cannot exclude some degree of opsonization contributing to the phagocytosis. However, the fact that both independent phagocytosis assays demonstrated impaired phagocytic capacity by TREM2 1/2 and TREM2 2/2 hPSCderived tMGs supports our conclusion that only TREM2 1/2 and TREM2 2/2 directly impair phagocytosis. Future studies assessing plaque phagocytosis from cryosections or slice cultures of human brain tissue from AD patients cocultured with TREM2 1/2 or TREM2 2/2 hPSC-derived tMG will be of interest for further confirmation of this phenotype.
In respect to the lack of a phagocytic phenotype for TREM2 1/R47H tMGs, one should take into account that the biggest risk factor of AD, aging, is not recreated in tMGs derived from hPSCs. One could consider generating tMGs by direct transdifferentiation of fibroblasts from elderly patients with LOAD with a TREM2
1/R47H mutation that may retain such an "aged signature" (as shown by Mertens et al., 2015 [48] for transdifferentiated neurons), once such protocols become available. Alternatively, TREM2
1/R47H
tMGs could be allowed to age by grafting in immunecompromised and microglia-depleted AD or SAMP8 mice and then reanalyzed or exposed to different ligands. Transcriptome analysis of such samples might reveal functions affected by this mutation upon aging.
Finally, transcriptome analysis revealed that loss of TREM2 is associated with a decreased expression of genes involved in extracellular matrix structure (integrin signaling) and transmembrane transporter activity, which suggests that loss of TREM2 may not only impair tMG-mediated phagocytosis but may in general affect the extent to which microglia can react/adapt to a changing microenvironment. TREM2 2/2 tMGs also expressed numerous genes involved in receptor-ligand activity, receptor-regulator activity, calcium ion binding, and cytokine activity more highly than WT tMGs, suggesting that TREM2 mutant tMGs might be proinflammatory (in agreement with the study by Hamerman et al. [21] ). Future studies will be of interest to further uncover deranged integrin and cytokine/chemokine signaling in TREM2 2/2 tMGs. To conclude, this is, to our knowledge, the first study using an ex vivo amyloid plaque clearance assay, highly relevant to AD, to study the effect of TREM2 mutations in human microglia-like cells. We demonstrated that homozygous or heterozygous loss of TREM2, but not presence of the TREM2 1/R47H mutation, directly impaired the ability of hPSC-derived monocytes and tMGs to phagocytose E. coli and clear amyloid plaques, which might thus contribute to AD pathology. Future mechanistic studies on human TREM2 1/R47H tMGs will be needed to determine why TREM2 1/R47H is associated with a 3-fold increased risk for LOAD. 
Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jalz.2018.09.006. 3. Future directions: The manuscript proposes more studies on aged human TREM2 1/R47H microglialike cells to further unravel why it poses the highest risk factor of late-onset Alzheimer's disease.
